Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

The advent of chimeric antigen receptor (CAR) T cell therapy has resulted in unprecedented
long-term clearance of relapse/refractory hematological malignancies in both pediatric and …

Tumour-Associated Macrophages (TAMs) are one of the pivotal components of the tumour
microenvironment. Their roles in the cancer immunity are complicated, both pro-tumour and …

Chimeric antigen receptor (CAR)-T cell therapy is one of the most promising advances in
cancer treatment. It is based on genetically modified T cells to express a CAR, which …

Despite being an integral part of the immune response in the tumor microenvironment
(TME), few studies have mechanistically elucidated eosinophil functions in cancer …

Adoptive cell therapy using chimeric antigen receptor (CAR) technology is one of the most
advanced engineering platforms for cancer immunotherapy. CAR-T cells have shown …

Fibroblast growth factor (FGF) signalling via FGF receptors (FGFR1–4) orchestrates fetal
development and contributes to tissue and whole-body homeostasis, but can also promote …

Background Chimeric antigen receptor (CAR)-T immunotherapy fails to treat solid tumors
due in part to immunosuppressive microenvironment. Excess lactate produced by tumor …

CAR (chimeric antigen receptor) T cell therapy has shown clinical success in treating
hematological malignancies, but its treatment of solid tumors has been limited. One major …

Natural killer (NK) cells, a unique component of the innate immune system, are inherent
killers of stressed and transformed cells. Based on their potent capacity to kill cancer cells …